Introduction {#S1}
============

Pain is a significant problem worldwide, and adequate pain relief remains an unmet medical need. Opioids acting at the mu-opioid receptor (MOR), a G-protein coupled receptor (GPCR), have been used therapeutically to control pain for centuries and remain the most commonly used class of analgesics and the most effective option for many patients. This, along with an increased focus on completely eliminating pain among physicians, has led to the recent huge increase in opioid prescriptions which, together with the addiction liability and respiratory depressant properties of opioid drugs, has driven the current opioid crisis and the resultant dramatic increase in opioid overdose deaths ([@B3]). Nonetheless, opioids remain the gold standard for pain control. Consequently, many approaches are being taken to target MOR in ways that enhance analgesic properties but reduce unwanted effects including, allosteric modulators ([@B9]), biased agonists that preferentially stimulate certain downstream pathways ([@B50]; [@B75]), compounds that target several opioid receptors simultaneously ([@B55]) or compounds with slow access to central MORs ([@B51]). In this review we discuss ways in which intracellular processes downstream of MOR activation by both exogenous opioid drugs and endogenous opioid peptides can be manipulated by regulator of G-protein signaling (RGS) proteins, and if this provides an avenue for the development of new analgesic molecules.

RGS Proteins {#S2}
============

Mu-opioid receptors are seven-transmembrane domain GPCRs that interact with G-proteins of the Gα~i/o~ and Gα~z~ classes that form a heterotrimer with their essential β and γ subunits ([Figure 1](#F1){ref-type="fig"}). At rest, the Gαβγ heterotrimer is bound to GDP. GPCR activation leads to dissociation of GDP from the Gα subunit and its replacement with GTP causing the Gα-bound GTP to separate from the βγ heterodimer. The now active Gα-GTP and βγ subunits interact with intracellular signaling partners, including inwardly rectifying potassium channels, calcium channels, phospholipase C, adenylyl cyclase isoforms, and components of the mitogen-activated protein kinase (MAPK) pathway. Intracellular signaling is terminated when endogenous GTPase activity of Gα hydrolyses GTP to GDP. The formed Gα-GDP then reassociates with the βγ heterodimer to terminate signaling. The enzymatic GTPase activity of the Gα~i/o/z~ subunits is slow with a GTP turnover rate of 2--5 per minute. This is not fast enough to allow a cell to respond to subsequent incoming signals. Here, RGS proteins come into play. These proteins bind to the switch regions of the active, GTP-bound Gα ([@B86]) and act as GTPase accelerating proteins or GAPs to increase rate of GTP hydrolysis by up to 100-fold. This drastically shortens the lifetime of the active Gα-GTP and βγ signaling proteins, resulting in a negative regulation of GPCR signaling, including signaling downstream of MOR ([Figure 1](#F1){ref-type="fig"}).

![**(A)** RGS proteins accelerate the hydrolysis of GTP bound to the Gα subunit to terminate signaling by reformation of the G-protein heterodimer. **(B)** RGS inhibitors slow the hydrolysis of GTP and so enhance signaling through Gα and βγ proteins.](fnmol-13-00005-g001){#F1}

The RGS proteins themselves constitute a 20-plus member family of intracellular regulatory proteins characterized by an RGS-homology (RH) domain and divided into subfamilies according to domain- and sequence-homology ([@B37]). RGS proteins vary in size and complexity from simple N- and C-terminal extensions to more complex proteins ([Table 1](#T1){ref-type="table"}). Some members of the family are selective for certain G-protein subtypes ([@B63]; [@B46]) and receptors ([@B94]; [@B90]). RGS proteins are variously expressed throughout the body including pain pathways in the central nervous system (CNS) where expression overlaps with MOR expression, particularly for RGS4 and the splice variant of RGS9, RGS9-2 ([@B29]; [@B61]; [@B30]; [@B87]). For example, the small RGS4 protein is expressed in many structures involved in the transmission and maintenance of pain, including the dorsal horn of the spinal cord, the periaqueductal gray (PAG), the thalamus, and the basal ganglia ([@B56]; [@B28]; [@B85]; [@B81]).

###### 

RGS subfamily characterization and expression.

  **RGS family**   **Domains present**               **Name**        **G-protein specificity**   **CNS expression**
  ---------------- --------------------------------- --------------- --------------------------- -------------------------------------------------------------
  RZ               Cysteine-string                   RGS17 (RGSZ2)   Gi, Gz, Gq                  Isocortex, OLF, HPF, CTXsp, PAL, TH, HY, MB, P, MY
                                                     RGS19 (GAIP)    Gi, Gz, Gq                  Isocortex, OLF, HPF, CTXsp, STR, PAL, TH, MB, P, MY, CB
                                                     RGS20 (RGSZ1)   Gi, Gz                      Isocortex, CTXsp, STR, PAL
  R4               N-terminal amphipathic sequence   RGS1            Gi, Gq                      N/A
                                                     RGS2            Gi \< Gq                    CTXsp, STR, PAL
                                                     RGS3            Gi, Gq                      TH, CB
                                                     RGS4            Gi, Gq                      Isocortex, OLF, HPF, CTXsp, STR, PAL, TH, HY, MB, P, MY, CB
                                                     RGS5            Gi, Gq                      Isocortex, OLF, HPF, CTXsp, STR, PAL, TH, HY, MB, P, MY, CB
                                                     RGS8            Gi, Gq                      Isocortex, OLF, HPF, CTXsp, STR, PAL, TH, HY, MB, P, MY, CB
                                                     RGS13           N/A                         N/A
                                                     RGS16           Gi, Gq                      TH
                                                     RGS18           Gi, Gq                      N/A
                                                     RGS21           Gi, Gq                      N/A
  R7               GGL-(Gβ5) DEP-(R9AP, R7BP)        RGS6            Go                          HPF, CTX ([@B1])
                                                     RGS7            Go \> Gi2 \> Gi1            Isocortex, OLF, HPF, CTXsp, STR, PAL, TH, HY, MB, P, MY, CB
                                                     RGS9            Go                          Isocortex, OLF, CTXsp, STR, PAL, HY
                                                     RGS11           Go                          Isocortex, OLF, HPF, CTXsp, STR, PAL, TH, HY, MB, P, MY
  R12              GoLoco-(Gα-GDP) RBD-(rap) PDZ     RGS10           Gi                          Isocortex, OLF, HPF, CTXsp, STR, PAL, TH, HY, MB, P, MY, CB
                                                     RGS12           Gi                          Isocortex, OLF, HPF, CTXsp, STR, PAL, TH, HY, MB, P, MY, CB
                                                     RGS14           Gi                          Isocortex, OLF, HPF, CTXsp, STR

List of RGS families and their respective domains, G-protein specificities, and expression in the mouse central nervous system. Isocortex, isocortex; OLF, olfactory; HPF, hippocampal formation; CTXsp, cortical subplate; STR, striatum; PAL, pallidum; TH, thalamus; HY, hypothalamus; MB, midbrain; P, pons; MY, medulla; CB, cerebellum. N/A = data not available. Taken from the Allen Brain Atlas (

https://mouse.brain-map.org

), except where stated.

Rationale for RGS Proteins as Potential Targets for Pain Management {#S3}
===================================================================

Intracellular proteins are not usually considered suitable drug targets due to their ubiquitous expression. In contrast, their differential expression patterns, selectivity for specific receptors and specificity for particular G-proteins, although not absolute, suggests the possibility that RGS proteins could be attractive drug targets for the management of pain by enhancing MOR-mediated signaling, leading to enhanced antinociception. Drugs inhibiting RGS activity could be beneficial in several ways. First, an enhancement of action of morphine and related exogenous opioid drugs would result in an opioid sparing effect, which would be especially advantageous if different RGS proteins controlled MOR signaling in those neuronal systems leading to antinociception versus those responsible for side-effects of respiration, reward, and constipation. Second, RGS inhibitors could produce analgesia in their own right by enhancing endogenous opioid peptide activity even in the absence of exogenous opioid drugs. Opioid peptides are released at spinal and supraspinal sites during pain ([@B48]; [@B11]; [@B62]; [@B97]; [@B38]; [@B92]) and also at peripheral sites ([@B78]). These endogenous peptides offer limited protection against pain but this effect is significantly increased if enzymatic peptide breakdown is prevented by so-called "enkephalinase inhibitors" ([@B19]; [@B58], [@B57]). Enhancement of endogenous opioid peptide signaling downstream of MOR by inhibition of RGS action should increase the analgesic efficacy of the peptides. Moreover, this approach has the advantage that, unlike enkephalinase inhibitors which globally increase enkephalin levels, the spatial and temporal release of the peptides would be retained and so RGS inhibitors will be effective only in those areas where the peptides are released in response to noxious stimuli, but not in areas responsible other actions of the peptides. A similar concept has recently been discussed with regard to positive allosteric modulators of MOR ([@B10]; [@B49]). Thirdly, there is evidence that the beneficial analgesic action of MOR agonists (and the endogenous opioid peptides) is due to signaling downstream of G-proteins, whereas the unwanted effects of respiratory depression and constipation may be mediated via the β-arrestin pathway ([@B66]; [@B89]; [@B50]; [@B75]). Since RGS proteins modulate the G-protein component of MOR signaling, but not the β-arrestin component, inhibitors of RGS proteins would be expected to show an increased therapeutic window separating the beneficial from unwanted effects ([Figure 1](#F1){ref-type="fig"}).

On the other hand, while RGS proteins are attractive analgesic targets and there is some degree of selectivity of expression and interaction with opioid receptors and G-proteins inhibition of RGS activity could regulate signaling downstream of numerous GPCRs. This suggests more nuanced strategies may be required to avoid the potential for off-target effects. Such targets might be the interface between RGS and opioid receptors or the complete RGS-Gα-opioid receptor complex rather than the RGS protein in isolation avoiding the potential for off-target effects.

RGS Insensitive Gα-Proteins {#S4}
===========================

Because RGS proteins constitute a large family of molecules it is difficult to know where to start when assessing their ability to control MOR signaling. An easier way is to develop a system which genetically knocks out all RGS GAP activity. This is feasible since replacement of a Gly in the "switch 3" region of the Gα protein ([@B86]) with Ser blocks the interaction between the RH region of RGS protein and the GTP-bound Gα subunit, without affecting any other properties of the Gα protein including GDP release, GTP hydrolysis, Gβγ binding, or interaction with the receptor. This mutation therefore prevents all GAP activity at a specific Gα protein. Thus, for example the Gly-Ser mutation in Gα~o~, promotes signaling downstream of MOR *in vitro* ([@B12]).

The behavioral effects of the mutation can be studied in mice with knock-in of RGS-insensitive Gα proteins (RGSi-Gα). This allows for proof of principle that inhibition of RGS activity is a viable strategy to provide antinociception and avoids the possibility of redundancy of GAP activity. Although on the minus side this approach does not identify the specific RGS protein(s) involved.

In assays using heat as the nociceptive source, mice expressing RGSi-Gα~o~ displayed an enhanced baseline withdrawal latency that was reversed by naltrexone, showing that endogenous opioid peptide activity is increased when RGS action is nullified ([@B43]). Similarly in the hot-plate test morphine-induced antinociception was enhanced; these finding were supported by an increased opioid-peptide mediated disinhibition of GABA release in the PAG, an important region for descending pain control ([@B44]). Surprisingly, in the tail withdrawal test the action of morphine was decreased, suggesting a permissive, not inhibitory, action for RGS proteins. Indeed, in the PAG, MOR activation of G-protein-gated inwardly rectifying potassium channels (GIRKs) was reduced for morphine and fentanyl in mice expressing RGSi-Gα~o~ proteins. No effect was seen on methionine enkephalin modulation of GIRK currents because this endogenous ligand appeared to use Gα~*i*~ proteins which are still regulated by RGS proteins in this genetic model ([@B52]). The results indicate that the RGS-mediated reduction in opioid-induced GIRK activation in mice expressing RGSi-Gα~o~ plays a role in opioid spinal antinociception, but not supraspinal, antinociception. These studies indicate that in general RGS protein GAP activity can produce negative and positive regulation of signaling depending on the intracellular effector(s) involved. One mechanism for this is RGS-mediated "kinetic scaffolding," the results of which depend on the proximity of the various components within a cell ([@B99]). In this model when effectors are close to the receptor RGS proteins are permissive because they act to sustain local concentrations of Gα-GDP necessary to maintain G-protein signaling. In contrast, further from the receptor where Gα-GDP is not depleted, RGS proteins suppress signaling and so are inhibitory. Alternatively, the opposite responses in morphine pharmacology observed could be due to roles for RGS proteins that have complex, for example, scaffolding functions. Additionally, since different neuronal circuits are involved in the two measures of morphine antinociception the loss of RGS negative regulation of Gα~o~ could reveal constitutive activity of opposing transmitted systems that use this G-protein, for example the nociceptin peptide system ([@B4]; [@B41]).

Specific Families of RGS Proteins {#S5}
=================================

While use of RGS-insensitive Gα~o~ proteins can provide proof of principle, conflicting results, such as in the antinociceptive assays discussed above highlight drawbacks in this approach. As such, examination of individual RGS proteins is needed to identify discrete pharmacological targets.

R4 Family {#S5.SS1}
---------

RGS4 itself has been extensively studied with respect to opioid-mediated signaling and antinociception This protein is distributed widely throughout the CNS where it regulates the pharmacology of MOR agonists ([Table 1](#T1){ref-type="table"}, reviewed in [@B87]). RGS4 is thought to interact directly with MOR *via* the fourth intracellular loop of the receptor (residues 329--355) and the RGS4 N-terminal domain ([@B47]). Removal of the N-terminal domain not only reduces RGS4-receptor interactions, but eliminates the receptor selectivity of endogenous RGS4 protein ([@B98]; [@B47]). When overexpressed in HEK293 cells, RGS4 is localized throughout the cytosol, nucleus, and plasma membrane ([@B73]) and binds only weakly to Gα~i/o~ proteins. However, following application of the MOR agonist \[D-Ala^2^, N-MePhe^4^, Gly-ol\]-enkephalin (DAMGO), expression shifts to the plasma membrane such that RGS4 is co-localized with the receptor ([@B47]) and the interaction between the two proteins is enhanced. In contrast, in SH-SY5Y human neuroblastoma cells that endogenously express RGS4 and MOR, knockdown of RGS4 did not affect responses to the MOR agonist morphine ([@B90]), suggesting that the ability of RGS4 to regulate MOR may be determined by the cell type and/or the agonist.

Intracerebroventricular (i.c.v.) administration in male mice of antisense-DNA against RGS4 resulted in a greater response to i.c.v. morphine in the tail withdrawal test compared to control given scrambled antisense ([@B23]). In contrast, constitutive RGS4 knockout mice do not display alterations in pain sensitivity in tests of acute nociception ([@B32]). This finding may be due to redundancy of RGS action. That is, since RGS4 is essentially an RH domain with very short N and C-termini, its loss may easily be compensated for by other RGS proteins ([@B14]), or by physiological compensatory mechanisms also regulated by RGS4. Indeed, further studies have implicated a critical role for RGS4 in the nucleus accumbens (NAc) in opioid antinociception ([@B34]). Conditional knockout of RGS4 only in this brain region reduces fentanyl and methadone antinociception, but not that of morphine, although it does act as a negative modulator of the rewarding effects of morphine, suggesting both agonist-specific and tissue-specific outcomes ([@B34]). To explain this discrepancy, the authors used immunoprecipitation experiments to indicate that fentanyl, but not morphine, recruits Gα~q~, rather than Gα~i/o~ proteins to MOR in the NAc and this competes with RGS4 for association with the receptor ([@B34]).

A more important role for RGS4 might be in chronic pain states, where RGS4 expression is dynamically regulated. For example, following sciatic nerve injury in the rat there is an up-regulation of RGS4 mRNA expression in the dorsal horn of the spinal cord, with no change in the mRNA of other RGS proteins measured (RGS6, 7, 8, 9, 11, 12, 14, 17, 19; [@B20]; [@B8]; [@B81]). At the same time rats become hypersensitive to noxious stimuli and the potency of MOR agonists decreases. Chronic pain states, such as following sciatic nerve injury are less sensitive to control by opioids than acute pain. Since RGS4 negatively regulates MOR signaling *in vitro* and there is significant overlap in expression of RGS4 and MOR within the spinal dorsal horn ([@B61]; [@B20]), this increased expression of RGS4 likely contributes to the loss of morphine potency in chronic pain. A report also indicates increases in RGS3 mRNA in the dorsal horn of the lumbar spinal cord after sciatic nerve ligation, although RGS4 levels decrease several days later; these effects may involve astrocyte RGS proteins ([@B15]). In support of a role for up-regulated RGS4 (and RGS3) in reducing the effectiveness of morphine, use of the inhibitor CCG-63802 ([Figure 2](#F2){ref-type="fig"}; [@B5]) to prevent RGS4 action attenuates hyperalgesia following nerve injury ([@B8]; [@B81]). This attenuation can be attributed to the rescue of tonically active endogenous antinociception systems, such as the enkephalins, although in one study using this inhibitor ([@B8]) endogenous cannabinoids rather than opioid endogenous opioids were implicated.

![Small molecule RGS inhibitors used in preclinical analgesic studies.](fnmol-13-00005-g002){#F2}

In contrast to changes in the spinal cord, RGS4 (as well as RGS3) message which is high in C-fiber sensory neurons in dorsal root ganglia (DRG) of the rat, has been reported to decrease following transection of the sciatic nerve ([@B13]), suggesting a location-dependent regulation of this transcript. A reduction in RGS4 would lead to an increase in GPCR, possibly MOR signaling. These divergent effects of up- or down-regulation of RGS proteins indicate a very fine level of pathophysiological control, although of course we do not know the specific GPCR target or targets of either the up-regulated RGS4/RGS3 in the dorsal horn or the down regulated RGS4 in the DRG. Resolving the reasons for the different findings on RGS3/4 levels after sciatic nerve injury and identifying the GPCRs that are modulated by these proteins would be an important step forward in developing RGS protein-based analgesics or analgesic adjuncts.

Injection of formalin into the mouse hind paw produces a biphasic hyperalgesia consisting of an early phase and a late phase. Mice lacking RGS4 are less hyperalgesic during the late phase ([@B95]; [@B2]). Moreover, mice lacking RGS4 recover more quickly from mechanical and cold hypersensitivity following inflammation, caused by Freund's Complete Adjuvant (CFA) injection into the hind paw, or nerve injury and show recovery of wheel running as a measure of pain-depressed behavior ([@B2]). One potential mechanism to explain both of these observations is the loss of negative regulation by RGS4 of endogenous antinociceptive signaling, possibly involving opioid peptides released in response to the persistent inflammatory pain ([@B62]; [@B97]; [@B92]). As with the nerve injury studies using CCG-63802 discussed above, results from this experimental paradigm support the notion that an inhibitor of RGS4 should enhance endogenous pain systems to produce analgesia, even in the absence of opioid drugs such as morphine. In support of this concept, the potency of the stable enkephalin analog DAMGO was increased 10-fold in the formalin test in animals lacking RGS4 compared to their wild-type controls ([@B95]), and intrathecal (i.t.) administration of the small molecule RGS4 inhibitor CCG-50014 ([Figure 2](#F2){ref-type="fig"}; [@B7]) to wild-type mice produced dose-dependent antinociception on its own that was blocked by the opioid antagonist naloxone, as well as enhancing the action of DAMGO ([@B95]).

Chronic pain is a highly complex condition. Using conditional knockdown of RGS4 [@B2] demonstrated that a major contributor to reversal of cold and mechanical hypersensitivity, but not recovery of pain-depressed wheel running, is the ventral posterolateral region of the thalamus, an important center for relaying nociceptive information. RNA sequence analysis of thalamic tissue from wild-type and RGS4 knockout mice after CFA-induced inflammatory pain showed decreased changes in gene expression in the knockout group and identified differences that included components of glutamatergic signaling, including an increased expression of membrane bound metabotropic glutamate receptor 2 which has been associated with recovery from hypersensitivity to sensory stimuli. Finally, the role for RGS4 in the anti-allodynic actions of tricyclic antidepressants and the NMDA receptor antagonist ketamine have been studied following sciatic nerve injury ([@B80]). The antiallodynic action of chronic low dose, but not high dose, desipramine was reduced in RGS4 knockout mice, whereas a low dose of ketamine produced antiallodynic behavior only in mice lacking RGS4. This difference highlights the complex roles of RGS4 and the fact that the GPCR targets for RGS4 have to be carefully considered when proposing inhibitors of RGS4 for the management of chronic pain. Nonetheless, whatever the mechanism involved in chronic pain and the drugs used for its management, these studies do suggest it is worth further investigating inhibitors of RGS4 as standalone treatments for chronic pain. The fact that two independently generated RGS4 knockout mouse lines, with distinct genetic backgrounds, show no overt behavioral abnormalities ([@B31]; [@B34]; [@B2]) provides support for RGS4 as a therapeutic target for pain management.

Roles for other R4 family members in modulating opioid function and analgesia have not been explored so extensively. RGS8 is enriched in the thalamus ([@B29]), a region dense in MOR expression, and RGS8 acts as a GAP for opioid-mediated signaling ([@B82]). Thus, it is possible that RGS8 interacts with MORs to modulate signaling in the thalamus to regulate processing of nociceptive information. Knockdown of RGS2 and RGS3 was reported to have no effect on baseline antinociception in the tail-flick test, but to inhibit the antinociceptive response to morphine and the endogenous opioid β-endorphin ([@B23]), suggesting, a positive role for these proteins in opioid antinociception. In contrast, after RGS16 knockdown, mice showed an increased antinociceptive response to morphine ([@B23]). The basis of these opposing effects of different R4 family members has not been adequately explored, although it has been suggested that distinct Gα interaction profiles between the different RGS proteins may be responsible for the diverse effects ([@B21], [@B23]).

Further studies of other RGS4 family members in both acute and chronic pain states are warranted. In particular, there are no published studies of family members other than RGS3 and 4 in chronic pain.

R7 Family {#S5.SS2}
---------

The R7 family of RGS proteins comprises RGS6, 7, 9--1, 9--2, and 11 ([@B37]). RGS9-1 and -2 are variants that differ only in the C-terminal tail. RGS9-1 is found only in the retina whereas RGS9-2 is brain specific, and highly expressed in the striatum. RGS7 and RGS9-2 form a heterodimer with the type 5 G-protein β (Gβ5) subunit. This facilitates correct folding and provides proteolytic stability. In addition, both RGS7/Gβ5 and RGS9-2/Gβ5 form complexes with a small palmitoylated protein R7 Binding Protein (R7BP), to control membrane localization and stability (reviewed in [@B45]).

In permeabilized C6 glioma cells expressing MOR and Gα~i2~, addition of the RH region of RGS7 did not affect DAMGO-induced inhibition of cAMP accumulation ([@B82]). When Gα~o~ was expressed instead of Gα~i2~, addition of the RH domain of RGS7 effectively inhibited the actions of DAMGO ([@B82]), suggesting that RGS7 selectively regulates the action of MOR depending on the G-protein expressed. This selectivity may be due to a lack of physical interaction between RGS7 and Gα~i2~, as increasing concentrations of Gα~i2~ disrupted the RGS4/Gα~o~ complex but not the RGS7/Gα~o~ complex ([@B82]). This suggests that the inability of RGS7 to regulate MOR signaling in cells expressing Gα~i2~ is due to a failure of RGS7/Gα~i2~ complex formation.

RGS9-2 interacts with MOR to prevent several events triggered by receptor activation. When RGS9-2 is located close to the cell membrane, it delays agonist-induced internalization of MOR ([@B64]). Further, morphine promotes the association of RGS9-2 with β-arrestin-2, a key component of MOR desensitization ([@B64]). This association is dampened in the presence of the structurally different MOR agonist fentanyl ([@B65]). Thus, RGS9-2 plays an important role in MOR regulation, as it negatively regulates signaling downstream of MOR and inhibits receptor endocytosis; however, these effects appear to be agonist-dependent.

Male mice given antisense-DNA against RGS7 or RGS9-2 into the ventricles, showed greater responses to morphine, DAMGO, and β-endorphin in the tail-flick test ([@B23]; [@B74]). Knockdown of RGS9-2 or RGS11 enhanced DAMGO antinociception to a greater degree than knockdown of RGS6 or RGS7 ([@B22]). The antinociceptive action of morphine toward an acute heat stimulus was reported to be enhanced in mice completely lacking RGS9 ([@B96]; [@B59]). The effects again appear to depend on the agonist studied. Thus, in the same RGS9 knockout mice, the analgesic efficacy of oxycodone was not changed, in either acute pain or in sciatic nerve injury induced pain ([@B26]) and whereas RGS9-2 knockout enhances the action of morphine in the hot-plate test, there is an inhibition of fentanyl- and methadone-mediated antinociception ([@B59]). This differential behavior across agonists that bind to the same orthosteric site on the MOR has been explained by the formation of dissimilar protein complexes following binding of ligand to MOR. In other words, there is a biased activation of receptor such that morphine promotes an association between RGS9-2 and Gα~i3~ whereas RGS9-2/Gα~*q*~ complexes are seen with the other ligands.

The opening of inwardly rectifying potassium (GIRK) channels is an important mechanism for antinociception downstream of MOR. Such channels are modulated by a complex of RGS 7 or 9 with Gβ5 downstream of MOR that is allosterically controlled by R7BP. Thus, as might be expected the loss of other components of this complex also result in altered antinociception. In the absence of R7BP there is a loss of negative regulation of MOR signaling, enhancing GIRK activity and so increasing morphine- and fentanyl induced antinociception ([@B83]; [@B100]). The R7BP null mice also show an enhanced basal latency to an acute thermal stimulus in the hot-plate assay ([@B100]), indicating enhanced endogenous antinociception by an increase in the activity of endogenous opioid peptides acting at MOR ([@B43]).

In support of an enhancement of endogenous opioid antinociception, RGS9 knockout mice exhibit a small degree of reduced hypersensitivity to the sensory component of both thermal and mechanical insult in early stages of neuropathic pain but exacerbation of affective components of the pain at later time points ([@B84]). The nerve injury in wild-type mice was seen to cause a transient reduction in levels of RGS9-2 in the spinal cord, explaining the reduced sensory hypersensitivity, although phenotypic changes in basal antinociceptive activity have not been ruled out, and a later decrease in RGS9-2 levels in the NAc, explaining the change in the affective response. Consequently, RGS9-2 appears to be a negative regulator of the sensory component but a positive regulator of the affective response ([@B84]). Since neuropathic pain can lead to depression in humans ([@B42]) this complication might preclude the use of inhibitors of RGS9-2 in the management of chronic pain.

R12 Family {#S5.SS3}
----------

The R12 family of RGS proteins consists of RGS10, 12, and 14. Little is known about how the R12 RGS family regulates MOR signaling and/or analgesia. Central knockdown of RGS12 and RGS14 increased morphine antinociception on the tail-flick test in the mouse, although there were no reported changes in baseline nociceptive thresholds ([@B23]) which may suggest a low or absent release of endogenous peptides or a lack of co-localization with RGS proteins. RGS14 knockdown reduced the development of acute tolerance following morphine exposure, and these behavioral changes occurred alongside increased MOR phosphorylation, which promotes internalization and recycling of the receptor ([@B68]). This suggests that in normal circumstances RGS14 limits agonist activity in a way that reduces both MOR phosphorylation (e.g., by GRKs) and β-arrestin-mediated endocytosis, leading to more robust receptor desensitization than in systems lacking RGS14 ([@B68]). More work is needed to understand the potential roles for the R12 family in regulating MOR signaling and antinociception.

RZ Family {#S5.SS4}
---------

The RZ family of RGS proteins consists of RGS17 (also known as RGSZ2), 19 (also known as G Alpha Interacting Protein/GAIP), and RGS20 (RGSZ1). Antisense knockdown of central RGSZ17 levels in male mice was seen to increase morphine and DAMGO antinociception, but also increased the rate of tolerance development ([@B25]). Knockdown of RGS19 in SH-SY5Y cells enhances MOR agonist-induced MAPK stimulation and adenylyl cyclase inhibition ([@B91]). Consequently, knockdown of RGS19 and RGS20, enhances the antinociceptive effects of morphine and DAMGO ([@B24]). In addition to these effects on antinociception, knockdown of either RGS19 or RGS20 increased the rate of analgesic tolerance development ([@B24]). Suppressing RGS20 function increased the antinociceptive efficacy of MOR agonists and delayed the development of morphine tolerance in mice ([@B27]). Thus, both RGS20 (RGSZ1) and RGS17 (RGSZ2) appear to play roles in regulating opioid antinociception and tolerance.

Treatment with morphine or DAMGO decreases associations between MOR and Gα~i2~ but increases associations between Gα~i2~ and RGSZ2 ([@B69]). This shift is transient, and the time course mimics the duration of antinociceptive tolerance following acute administration of morphine, such that Gα~i2~ interactions have returned to normal at time points when acute antinociceptive tolerance has waned ([@B69]). A similar process occurs with RGSZ2 and Gα~z~, with MOR agonists increasing association between these proteins while decreasing Gα~z~/MOR association ([@B25]). Together these results suggest that all RZ RGS proteins are capable of both inhibiting MOR agonist-induced antinociception and reducing the development of tolerance following agonist exposure, likely through regulation of Gα~z~ and Gα~i2~ ([@B24], [@B25]; [@B69]).

To date, no studies related to antinociception have been performed in mice with constitutive or conditional genetic knockout of any members of the RGS RZ family.

RGS Regulation of Signaling and Antinociception Downstream of Other Opioid Receptors {#S6}
====================================================================================

All members of the opioid receptor family are involved in some way in the modulation of pain and have been the subject of study in relation to their interactions with RGS proteins.

The Delta Opioid Receptor (DOR) {#S6.SS1}
-------------------------------

There is much evidence that RGS4 modulates signaling downstream of the delta opioid receptor (DOR) and this in turn leads to increases in antinociceptive properties of agonists at these receptors. For example, purified RGS4 reverses the enkephalin-mediated DOR inhibition of adenylate cyclase activity in NG108-15 cells ([@B36]). In HEK293 cells, RGS4 overexpression similarly reduced DOR agonist-stimulated signaling and increased the degree of DOR internalization ([@B47]). In agreement with these overexpression studies, a 90% reduction of RGS4 in SH-SY5Y cells significantly increased the ability of DOR agonists to inhibit adenylyl cyclase and activate MAPK ([@B90]) and in mouse brain the small molecule DOR agonist SNC80 increased striatal MAPK phosphorylation to a greater degree in RGS4 knockout animals, than their littermate controls ([@B16]). Mutagenesis studies have identified the C-terminus of DOR as the site of interaction with RGS4 and work using molecular dynamics simulations and *in vitro* pull-down experiments, has isolated this to 12 amino-acid residues in helix 8 of DOR and to the first 17 N-terminal residues of RGS4 ([@B40]).

Similar to the enhancement of MOR-mediated antinociception, the potency of SNC80 is increased in nitroglycerin-induced hyperalgesia in mice expressing RGSi-Gα~o~ ([@B16]). In addition, RGS4 knockout mice show an enhanced antinociceptive response to SNC80 compared to their wild-type littermate controls ([@B16]). Importantly, in both the RGSi-Gα~o~ knock-in mice and the RGS4 knockout mice the enhancement of DOR-mediated antinociception occurs without an increased ability of SNC80 to cause convulsions, a serious side effect of DOR agonists, thus increasing the preclinical therapeutic window of this DOR agonists.

RGS19 (GAIP) has also been studied with respect to DOR signaling. Purified RGS19, like RGS4 acts as a GAP for DOR signaling in NG108-15 cells ([@B36]). In contrast DOR signaling in SH-SY5Y cells to adenylate cyclase or MAPK was not sensitive to knockdown of RGS19 ([@B91]) and knockdown of RGS19 failed to modulate antinociceptive responses to DOR agonists, DPDPE and deltorphin ([@B24]). This could suggest the experiments in NG108-15 cells that RGS19 is acting as a non-selective GAP. Conversely, there is other evidence of a role for RGS19 in DOR signaling. Thus, in HEK cells Flag-tagged DOR and heterologously expressed RGS19 are found in different cellular compartments; RGS19 in clathrin-coated membrane regions and DOR near Gα~i3~ in non-clathrin-coated regions ([@B17]). Following DOR agonist treatment, activated GTP-bound Gα~i3~ and RGS19 co-localize in clathrin-coated regions to form a complex when RGS19 acts as a GAP to promote GTP hydrolysis returning Gα~i3~ to its GDP bound inactive form. This is reminiscent of the proposed process, described above, where MOR agonist treatment shifts Gα~i2~ and Gα~z~ from a complex with MOR to a complex with RGSZ-2 ([@B69]).

The Kappa Opioid Receptor {#S6.SS2}
-------------------------

Little published work is available on how RGS proteins affect signaling and antinociception downstream of the kappa opioid receptor, KOR. The genetic loci for RGS20 and KOR are separated by only approximately 600 base pairs, suggesting that these proteins may be co-regulated ([@B77]). In *Xenopus* oocytes, RGS4 expression inhibits GIRK1 and GIRK2 downstream of KOR activation, and the presence of RGS4 appears to counteract cellular adaptations to sustained KOR agonist treatment ([@B88]). Further, RGS2 and RGS4 bind to different domains of KOR to reduce signaling of this receptor to adenylate cyclase and the MAP kinase pathway in HEK cells ([@B60]). In PC12 cells stably expressing KOR, agonist application increased RGS4 mRNA expression in a KOR antagonist reversible manner, a process that may contribute to desensitization of KOR agonist responses ([@B54]). Downstream of KOR, RGS12 attenuates G-protein signaling and promotes β-arrestin ([@B33]). Since β-arrestin is thought to promote unwanted effects of KOR agonists, including aversion, an inhibitor of RGS12 would be expected to promote G-protein signaling and therefore analgesia without dysphoria, as indicated in [Figure 1](#F1){ref-type="fig"}.

The Nociceptin Receptor {#S6.SS3}
-----------------------

The genetic loci for the nociceptin (NOP) receptor and RGS19 neighbor each other, with RGS19 found only 83 base pairs from the 5′ end of the gene encoding NOP receptor ([@B39]; [@B93]). This 83 base pair region functions as a bidirectional promoter for both genes ([@B39]). Despite this close co-regulation RGS19 and NOP receptor expression show differences, for example, RGS19 is found in both undifferentiated and differentiated NT2 cells, while the NOP receptor is expressed only after differentiation ([@B39]). Nociceptin has both pro- and anti-nociceptive activity ([@B67]), so it will be of interest to see how the balance of these activities is controlled by members of the RGS protein family.

Can We Target RGS Proteins? {#S7}
===========================

An extensive amount of research has been conducted at both the molecular/cellular and behavioral levels on the interaction between MOR and certain RGS proteins, especially RGS4 and RGS9-2, but effects of RGS proteins on other opioid receptors is in its infancy. Nonetheless, the findings summarized above suggest that RGS proteins are attractive targets that may allow more precise control of opioid analgesic effects, and RGS inhibiting molecules may even have stand-alone analgesic efficacy.

In this regard the first attempts to develop inhibitors were peptides designed on the Gα interface with RGS proteins ([@B72]). To date, no small molecules targeting this large surface region have been published. On the other hand, a number of small molecules that act at a least one cysteine distant from the interaction surface have been developed ([@B71], [@B70]; [@B5], [@B7]; [@B53]; [@B79]). Inhibition occurs by covalent modification of this cysteine, although the interaction of some inhibitors with RGS protein can be reversed ([@B79]). Because many RGS proteins have a cysteine in the RH domain these inhibitors act somewhat promiscuously, although some degree of selectivity can be obtained. For example, CCG-203769 which inhibits RGS4, is 10-fold less potent at inhibiting RGS19, but has a very high selectivity over other members of the RGS family ([@B6]). Similarly, CCG-50014 inhibits both RGS4 and RGS19 and is selective for these RGS proteins over RGS8 and RGS16 ([@B7]), None of the small molecule inhibitors identified to date act at RGS6 or RGS7 ([@B35]) which lack a cysteine in the RH domain, although it is worth noting that RGS9 does have a cysteine in the same position at the sensitive cysteine in RGS19. Of interest is that studies have now shown CCG-50014 also inhibits RGS1,5,14, and 17 and in fact is most potent at RGS 14 ([@B35]). This could be significant given the, albeit limited, knowledge on the role of RGS14 in morphine antinociception ([@B23]; [@B68]). Thus the finding that CCG-50014 enhances the inhibitory effects of both MOR and DOR agonists *in vitro* ([@B6]), and, as mentioned earlier produces naloxone-reversible antinociception in a mouse model ([@B95]), may not be due only to its action as an inhibitor of RGS4.

A report by [@B76], explores the structural determinants of RGS inhibitor selectivity. In general, inhibitors such as CCG-50014 preferentially inhibit RGS proteins with a greater degree of structural flexibility. Thus, increasing the number of interhelical salt bridges present in the RGS protein structure reduces flexibility, and decreases the relative affinity of CCG-50014 for RGS4 or RGS8. Conversely, mutations which decrease the rigidity of RGS4 and RGS8 increase CCG-50014 binding to these targets. In addition, a distinct class of small molecules, BMS-195270 and BMS-192364 were identified in an *in vitro* assay for bladder contraction using a chemical genetics screen. These compounds gave results consistent with a mechanism whereby they interfere with the Gα~*q*~/RGS complex downstream of muscarinic receptors to terminate signaling ([@B18]). Compounds with activity at Gα~i/o~/RGS complexes that are likely to be effective downstream of opioid receptors have not been described to our knowledge.

Overall, there is evidence for the involvement of certain RGS proteins in the control of pain and analgesia, although many of these studies measured only acute antinociception and have not been replicated or followed up. Moreover, the ability to selectively target these proteins, especially with reversible ligands is also very limited. As understanding of the binding modes for current RGS inhibitors continues to increase and new inhibitors are discovered, a more thorough understanding of the role of RGS proteins in pain and analgesia will become increasingly important.
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